Abcellera announces that the u.s. patent trial and appeal board upholds microfluidic cell culture patent

Vancouver, british columbia--( business wire )--abcellera (nasdaq: abcl) today announced that the united states patent and trademark office's patent trial and appeal board (ptab) has ruled in favor of abcellera in an inter partes review (ipr) filed by berkeley lights, inc. (berkeley lights) that challenged abcellera's u.s. patent no. 10,087,408 (the ‘408 patent). abcellera's ‘408 patent is directed to microfluidic devices and using such devices to culture cells, monitor a response, and recover selected cells.
ABCL Ratings Summary
ABCL Quant Ranking